Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price fell 4.4% on Wednesday . The stock traded as low as $0.37 and last traded at $0.39. 78,251,078 shares traded hands during trading, an increase of 160% from the average session volume of 30,044,369 shares. The stock had previously closed at $0.40.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Monday. They issued a "hold" rating for the company.
Get Our Latest Stock Report on TNXP
Tonix Pharmaceuticals Stock Performance
The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company's 50 day moving average is $0.22 and its 200-day moving average is $0.41. The company has a market capitalization of $72.01 million, a P/E ratio of -0.01 and a beta of 2.23.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Further Reading
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
